1. Ивашкин В.Т. Национальное руководство «Гастроэнтерология». М.: ГЭОТАР, 2008.
2. Баранская Е.К. Боль в животе: клинический подход к больному и алгоритм лечения. Место спазмолитической терапии в лечении абдоминальной боли. Фарматека. 2005; 14 (109).
3. Гриневич В.Б. и др. Особенности терапии функционального панкреатического расстройства сфинктера Одди у пациентов с жировой болезнью печени на фоне алиментарной формы ожирения. Лечащий врач. 2011; 7.
4. Самсыгина Г. Дисбактериоз. Диагноз устарел? Биоценоз желудочно-кишечного тракта новорожденного. http://www. 9months.ru/press/3_02/37
5. Камардина Т.В., Глазунов И.С., Соколова Л.А., Лукичева Л.А. Эпидемия курения среди женщин России. http://www.cindi.ru/ smoking-w003rus.doc.
6. http://www.9months.ru/press/3_02/37
7. http://lib.rus.ec/b/95224/read
8. http://painconsortium.nih.gov/MAPPResearch
9. Шульпекова Ю.О. Хроническая тазовая боль у женщин. Рус. мед. журн. 2011; 19 (20): 1232–7.
10. Allescher HD et al. Effect of N-Butilscopolamine on sphincter of Oddi Motility in Patients during Routine ERCP – a Manometric Study. Endoscopy 1989; 22: 160–3.
11. APIC Guide to Preventing Clostridium difficile Infections. http://www.apic.org/Professional-Practice/Implementation-guides
12. Azzam N, Aljebreen AM, Alharbi O, Almadi MA. Prevalence and clinical features of colonic diverticulosis in a Middle Eastern population. World J Gastrointest Endosc 2013; 5 (8): 391–7.
13. Biesiekierski JR et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106 (3): 508–14.
14. Boivin M, Habal FM, Oleksyn C. Role of antispasmodics in the self-treatment of abdominal cramping and pain. www.rxBriefCase.com.
15. Cairns MD, Stabler RA, Shetty N, Wren BW. The continually evolving Clostridium difficile species. Future Microbiol 2012; 7 (8): 945–57.
16. Choi Y, Kraft N, Zimmerman B. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol 2003; 42: 233–8.
17. Cuomo R, Barbara G, Andreozzi P et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 2013.
18. Deshpande A, Pant C, Pasupuleti V et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012; 10 (3): 225–33.
19. Di Sabatino A, Corazza GR. Nonceliac gluten sensitivity: sense or sensibility? Ann Intern Med 2012; 156 (4): 309–11.
20. Gibson PR, Newnham E, Barrett JS et al. Review article: fructose malabsorption and the bigger picture. Aliment Pharmacol Ther 2007; 25 (4): 349–63.
21. Godfrey JD, Brantner TL, Brinjikji W et al. Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology 2010; 139 (3): 763–9.
22. Golder М, Ster IC, Babu P et al. Demographic determinants of risk, colon distribution and density scores of diverticular disease. World J Gastroenterol 2011; 17 (8): 1009–17.
23. Feliciano LS, Matias V, Lapena S et al. Breast feeding and early life immunomodulation. Pediatr Allergy Immunol 2012; 23 (7): 690–1.
24. Ford AC, Talley NJ, Spiegel BMR et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313.
25. Hilton S. The wonder of breast milk. Pract Midwife 2013; 16 (7): 37–8, 40.
26. Howden BP, Holt KE, Lam MMC et al. Genomic Insights to Control the Emergence of Vancomycin-Resistant Enterococci, mBio 2013; 4 (4): e00412–13.
27. Iida H, Ohkubo H, Inamori M et al. Epidemiology and clinical experience of chronic intestinal pseudo-obstruction in Japan: a nationwide epidemiologic survey. J Epidemiol 2013; 23 (4): 288–94.
28. Johansson K, Sundstrom J, Marcus C et al. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes (Lond) 2013.
29. Mann K, Hermann D, Heinz A. One hundred years of alcoholism: the twentieth century. Alcohol Alcoholism 2000; 35 (1): 10–5. http://literball.ru/tendency/tendency1.html
30. Lacyon BE et al. On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. Scand J Gastroenterol 2013; 48: 926–35.
31. Lundin KEA, Alaedini А. Non-celiac Gluten Sensitivity. Gastrointest Endoscopy Clin N Am 2012; 22723–34.
32. Miwa H et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 2004; 9 (1): 9–16.
33. Mueller-Lissner S, Tytgat GN, Paulo LG et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006; 23 (12): 1741–8.
34. Mulder I, Hoogenveen RT, van Genugten ML et al. Smoking cessation would substantially reduce the future incidence of pancreatic cancer in the European Union. Eur J Gastroenterol Hepatol 2002; 14 (12): 1343–53.
35. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol 2013; 108 (6): 959–61.
36. Pilgrim SM, Hart AR, Speakman CT. Diverticular disease in younger patients – is it clinically more complicated and related to obesity? Colorectal Dis 2013. doi: 10.1111/codi.12225.
37. Samuels LA. Pharmacotherapy Update: Hyoscine Butylbromide in the Treatment of Abdominal Spasms Clinical Medicine: Therapeutics 2009: 1647–55.
38. Sarna SK. Lessons Learnt from Post-Infectious IBS. Front Physiol 2011; 2: 49.
39. Schäfer E, Ewe K. The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon Fortschr Med 1990; 108 (25): 488–92.
40. Stanghellini V, Cogliandro RF, De Giorgio R et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol 2005; 3: 449–58. doi: 10.1016/S1542-3565(04)00675-5
41. Strate LL, Modi R, Cohen E, Spiegel BM. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol 2012; 107 (10): 1486–93.
42. Sullivan SN. Functional Abdominal Bloating with Distention. ISRN Gastroenterol 2012; 2012: 721820.
43. Tadros M, Majumder S, Birk JW. A review of ischemic colitis: is our clinical recognition and management adequate? Expert Rev Gastroenterol Hepatol 2013; 7 (7): 605–13.
44. Tytgat GN. Hyoscine Butylbromide. A review of its use in the treatment of abdominal cramping and pain. Drugs 2007; 67 (9): 1343–57.
45. Tytgat GN. Hyoscine butylbromide – a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures. Curr Med Res Opin 2008; 24 (11): 3159–73.
46. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013; 144 (6): 1252–61.
47. Wahnschaffe U, Schulzke J et al: Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 7: 844–50.
48. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001; 121: 1329–39.
49. Ward TL, Hosid S, Ioshikhes I, Altosaar I. Human milk metagenome: a functional capacity analysis. BMC Microbiol 2013; 13: 116.
50. N-butyl Hyoscine Bromide in the Treatment of some Clinical Conditions with Spasm and Pain, by doctors: Luis Llaca Victoria and Juan Martínez Medra­­­no.
51. Brian E. Lacy et al. On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. Scand J Gastroenterol 2013; 48: 926–35.
52. Galassi P, Goldoni S, Iorio B, Manieri C. Oral tyropramide versus butylscopolamine bromide in patients suffering from urogenital spasms. Clinical randomised study, Progr Med (Roma) 1985; 41: 307–10.

Е.К.Баранская, Ю.О.Шульпекова

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России